Harm reduction, hepatitis C and opioid pharmacotherapy: an opportunity for integrated hepatitis C virus-specific harm reduction.
Hallinan R, Byrne A, Dore GJ.
Hallinan R, et al. Among authors: byrne a.
Drug Alcohol Rev. 2007 Jul;26(4):437-43. doi: 10.1080/09595230701373933.
Drug Alcohol Rev. 2007.
PMID: 17564882
While harm reduction advocates, policy makers and practitioners have a right to be proud of the impact of interventions such as needle and syringe programmes on HIV risk, we can be less sanguine about the ongoing high levels of HCV transmission among injecting drug users ( …
While harm reduction advocates, policy makers and practitioners have a right to be proud of the impact of interventions such as needl …